专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011067283A1 NOVEL PEPTIDYL ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASES 审中-公开
标题翻译：新型磷酸二氢羟丙基胆碱酯酶
公开(公告)号：WO2011067283A1
公开(公告)日：2011-06-09
申请号：PCT/EP2010/068630
申请日：2010-12-01
申请人： NOVO NORDISK A/S , SHAW, Allan Christian
发明人： SHAW, Allan Christian
IPC分类号： C07K14/195 , C12N9/88
CPC分类号： C12N9/88 , C07K14/575 , C12P21/00 , C12Y403/02005
摘要： The present patent application concerns an enzyme capable of catalysing the conversion of a α-hydroxyglycine to an α-amide and the use of such enzymes for producing a C-terminal α-amidated peptide.
摘要翻译：本专利申请涉及能够催化α-羟基甘氨酸转化为α-酰胺的酶以及这种酶用于制备C-末端α-酰胺化肽的酶。

2. 发明申请

WO2015197446A1 MIC-1 FUSION PROTEINS AND USES THEREOF 审中-公开
标题翻译： MIC-1融合蛋白及其用途
公开(公告)号：WO2015197446A1
公开(公告)日：2015-12-30
申请号：PCT/EP2015/063596
申请日：2015-06-17
申请人： NOVO NORDISK A/S
发明人： SHAW, Allan Christian , HELGSTRAND, Charlotte , SANDRINI, Michael Paolo Bastner , JØRGENSEN, Sebastian Beck , THØGERSEN, Henning , SASS-ØRUM, Kristian , HASTRUP, Sven , ANDERSEN, Kim Vilbour
IPC分类号： A61K39/00 , C07K14/475
CPC分类号： A61K38/18 , A61K38/19 , A61K38/385 , A61K47/643 , A61K47/65 , C07K14/00 , C07K14/475 , C07K14/52 , C07K14/765 , C07K2319/31
摘要： The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
摘要翻译：本发明涉及MIC-1融合蛋白。更具体地，涉及包含融合蛋白C末端的MIC-1蛋白或其类似物的融合蛋白的化合物和通过肽接头相连的融合蛋白N末端的人血清白蛋白的功能变体。本发明的化合物具有MIC-1活性。本发明还涉及包含这些化合物和药学上可接受的赋形剂的药物组合物，以及该化合物的医疗用途。

3. 发明申请

WO2014187960A1 REMOVAL OF N-TERMINAL EXTENSIONS FROM FUSION PROTEINS 审中-公开
标题翻译：从融合蛋白中去除N-末端延伸
公开(公告)号：WO2014187960A1
公开(公告)日：2014-11-27
申请号：PCT/EP2014/060669
申请日：2014-05-23
申请人： NOVO NORDISK A/S
发明人： SHAW, Allan Christian
IPC分类号： C12P21/06 , C12N15/62
CPC分类号： C12P21/06 , C12N9/485 , C12N9/506 , C12Y304/14011 , C12Y304/22028
摘要： This invention relates to an improved method for manufacturing a matured protein with its intact sequence from a fusion protein. More specifically, the present invention relates to enzymatic methods using picornaviral 3C protease and Xaa-Pro dipeptidyl aminopeptidase for the removal of an N-terminal extension from a fusion protein, and the use of these methods to produce recombinant products with the correct N-terminal sequence.
摘要翻译：本发明涉及用融合蛋白的完整序列制备成熟蛋白质的改进方法。更具体地说，本发明涉及使用微晶核蛋白病毒3C蛋白酶和Xaa-Pro二肽基氨基肽酶从融合蛋白中除去N-末端延伸的酶法，以及使用这些方法生产具有正确N-末端的重组产物序列。

4. 发明申请

WO2016102580A1 ALPHA-1-ANTITRYPSIN (A1AT) FUSION PROTEINS AND USES THEREOF 审中-公开
标题翻译： ALPHA-1-ANTITRYPSIN（A1AT）融合蛋白及其用途
公开(公告)号：WO2016102580A1
公开(公告)日：2016-06-30
申请号：PCT/EP2015/080998
申请日：2015-12-22
申请人： NOVO NORDISK A/S
发明人： SHAW, Allan Christian
IPC分类号： C07K14/495 , C07K14/81 , A61K38/18
CPC分类号： C07K14/8125 , A61K38/00 , C07K14/475 , C07K2319/31
摘要： The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C- terminus of the fusion protein and a functional variant of human A1AT (A1AT) at the N- terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
摘要翻译：本发明涉及MIC-1融合蛋白。更具体地说，本发明涉及包含融合蛋白的C-末端的MIC-1蛋白或其类似物的融合蛋白的化合物和在融合蛋白的N-末端的人A1AT（A1AT）的功能变体，肽接头。本发明的化合物具有MIC-1活性。本发明还涉及包含这些化合物和药学上可接受的赋形剂的药物组合物，以及该化合物的医疗用途。

5. 发明申请

WO2014191455A1 METHODS FOR PRODUCING PEPTIDES USING ENGINEERED INTEINS 审中-公开
标题翻译：使用工程化产品生产胶囊的方法
公开(公告)号：WO2014191455A1
公开(公告)日：2014-12-04
申请号：PCT/EP2014/061048
申请日：2014-05-28
申请人： NOVO NORDISK A/S
发明人： SHAW, Allan Christian , NORRILD, Jens Christian , ALBERTSEN, Louise
IPC分类号： A61K38/22 , C07K14/575 , C07K7/00 , C12N15/09 , C12N15/62
CPC分类号： C07K14/47 , C07K1/006 , C07K7/00 , C07K14/575 , C07K2319/00 , C07K2319/92 , C12N9/90 , C12N15/09 , C12N15/625
摘要： The present invention provides a method for producing peptides by recombinant means. The peptides are expressed as part of a fusion protein comprising the target peptide and an engineered intein. The invention also provides the engineered inteins, fusion proteins comprising these, and DNA constructs coding for these fusion proteins. Upon thiol-induced cleavage of the fusion protein the carboxy-terminal a-thioester of the target peptide is obtained. The carboxy-terminal α-thioester can in principle react with any nucleophile and the strategy therefore allows a wider range of carboxy-terminal modifications such as chemical ligation, bioconjugation, or amidation. The engineered inteins of the present invention are minimized in size and has a cysteine mutation in the position corresponding by alignment to position 3 of Mxe GyrA intein (SEQ ID NO:1 ) leading to increased expression levels of the fusion protein and higher yields of the isolated target peptide, thus making the method of the invention suitable for production scale.
摘要翻译：本发明提供了通过重组方法制备肽的方法。肽被表达为包含靶肽和工程化内含肽的融合蛋白的一部分。本发明还提供了工程化的内含肽，包含它们的融合蛋白以及编码这些融合蛋白的DNA构建体。在硫醇诱导的融合蛋白切割时，获得了靶肽的羧基末端α-硫酯。羧基末端α-硫酯可以原则上与任何亲核试剂反应，因此该策略允许更广泛的羧基末端修饰，如化学连接，生物共轭或酰胺化。本发明的工程化内含子在尺寸上最小化，并且在对应于Mxe GyrA内含肽（SEQ ID NO：1）的位置3的对应位置处具有半胱氨酸突变，导致融合蛋白的表达水平升高，并且更高的产量分离的靶肽，从而使本发明的方法适合于生产规模。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式